Pricing Log in Create free account

Genenta Science S.p.A. Unsponsored ADR (GNTA) vs TransCode Therapeutics Inc. (RNAZ)

Genenta Science S.p.A. Unsponsored ADR and TransCode Therapeutics Inc. are both Biotechnology companies. Genenta Science S.p.A. Unsponsored ADR and TransCode Therapeutics Inc. are of similar size ($32.3M and $30.5M). Across the 7 metrics below, TransCode Therapeutics Inc. leads on 4 and Genenta Science S.p.A. Unsponsored ADR on 3.

Valuation

Metric GNTA RNAZ Biotechnology median
P/E — n/m 8.50
P/S n/m n/m 9.71
P/B n/m n/m 2.13
Price to free cash flow n/m n/m 20.82
EV/EBITDA n/m 0.10 0.64
EV/Sales n/m n/m 9.21
Earnings yield — (3,080.59%) (33.15%)
Free cash flow yield 0.00% (1,390.70%) (25.50%)

Profitability

Metric GNTA RNAZ Biotechnology median
Gross margin — 0.00% 65.16%
Operating margin — 0.00% 0.00%
Net margin — 0.00% 0.00%
Free cash flow margin 0.00% 0.00% 0.00%
Return on equity 0.00% 429.61% (56.36%)
Return on assets 0.00% (58.12%) (48.04%)
Return on invested capital 0.00% 0.00% 0.00%

Growth

Metric GNTA RNAZ Biotechnology median
Revenue growth (TTM) — — 6.02%
EPS growth (last fiscal year) 30.19% 96.02% 30.26%
Revenue growth, 5-year CAGR — — 9.41%
Net income growth, 5-year CAGR 0.00% 0.00% 0.00%

Health

Metric GNTA RNAZ Biotechnology median
Debt to equity 0.35 0.00 0.00
Current ratio 14.16 1.97 4.72
Net debt to EBITDA 3.12 0.64 0.96

Dividend

Metric GNTA RNAZ Biotechnology median
Dividend yield — — 0.09%
Payout ratio — — —

Size

Metric GNTA RNAZ Biotechnology median
Market cap 32.28m 30.48m 135.18m

Compare with another peer

Any metric, up to five companies and an Excel export Powerpack